Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.

Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.

Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane conductance regulator (CFTR) and epithelial sodium channel (ENaC) activity. We evaluated methods to detect changes in chloride and sodium transport by NPD based on a secondary analysis of a Phase II CFTR-mod...

Full description

Bibliographic Details
Main Authors: Steven M Rowe, Bo Liu, Aubrey Hill, Heather Hathorne, Morty Cohen, John R Beamer, Frank J Accurso, Qunming Dong, Claudia L Ordoñez, Anne J Stone, Eric R Olson, John P Clancy, VX06-770-101 Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3724869?pdf=render

Internet

http://europepmc.org/articles/PMC3724869?pdf=render

Similar Items